---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-012335"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:47:23.816176+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mineralys prices $175M public offering (12.96M shares at $13.50); net proceeds ~$164.2M

## Summary
- Offering of 12,962,962 shares at $13.50; gross proceeds $175M; net proceeds ~$164.2M.
- Underwriters have 30-day option for additional 1,944,444 shares, adding up to $26.3M.
- Proceeds to fund lorundrostat clinical development, R&D, manufacturing, and pre-commercialization.
- Joint book-runners: BofA Securities, Evercore ISI, Goldman Sachs, Stifel, Wells Fargo.
- Expected to close March 13, 2025; subject to customary conditions.

## SEC filing metadata
- accession: 0001628280-25-012335
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000162828025012335/0001628280-25-012335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000162828025012335/mlys-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-012335
- JSON: https://secwatch.observer/filing/0001628280-25-012335.json
- Plain text: https://secwatch.observer/filing/0001628280-25-012335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.